Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 19.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 157,024 shares of the company's stock after purchasing an additional 25,275 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.13% of Vaxcyte worth $17,943,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Riverview Trust Co purchased a new position in shares of Vaxcyte during the 3rd quarter worth $27,000. Fifth Third Bancorp purchased a new position in shares of Vaxcyte during the 2nd quarter worth $35,000. Blue Trust Inc. grew its holdings in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the period. J.Safra Asset Management Corp grew its holdings in shares of Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after purchasing an additional 526 shares during the period. Finally, Quest Partners LLC purchased a new position in shares of Vaxcyte during the 2nd quarter worth $70,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Price Performance

Shares of PCVX traded down $2.26 during mid-day trading on Monday, reaching $92.08. The company's stock had a trading volume of 304,887 shares, compared to its average volume of 903,837. Vaxcyte, Inc. has a 12-month low of $52.74 and a 12-month high of $121.06. The stock has a market cap of $11.48 billion, a PE ratio of -20.51 and a beta of 1.01. The company's 50 day moving average is $105.60 and its 200 day moving average is $90.49.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same period in the previous year, the company posted ($0.91) EPS. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PCVX shares. BTIG Research increased their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Jefferies Financial Group increased their price target on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Leerink Partners increased their price target on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research report on Tuesday, September 3rd. Finally, Bank of America increased their price target on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $147.50.

Insider Buying and Selling

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $106.80, for a total value of $854,400.00. Following the transaction, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $21,968,226. This trade represents a 3.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 2,366 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the sale, the chief executive officer now directly owns 137,398 shares of the company's stock, valued at $14,274,278.22. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 102,464 shares of company stock worth $11,455,576 in the last quarter. 3.10% of the stock is owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.